FPN || Diabetes & Metabolic Disorders

FDA to probe saxagliptin’s heart failure risk

Posted on: 11/02/2014 - 20:15

The U.S. Food and Drug Administration will investigate the possible association between treatment with the type 2 diabetes drug saxagliptin and an increased rate of hospitalizations for heart failure...

Field of Interest: Endocrinology

Type: News Item

‘Obesity paradox’ refuted

Posted on: 15/01/2014 - 22:00

Mortality is not lower among adults with diabetes who were overweight or obese at diagnosis than among those who were of normal weight, as has been suggested by proponents of the "obesity...

Field of Interest: Endocrinology

Type: News Item

FDA approves dapagliflozin for type 2 diabetes

Posted on: 08/01/2014 - 20:20

Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, has been approved for the treatment of type 2 diabetes with a requirement that the manufacturer conduct postmarketing studies that address...

Field of Interest: Endocrinology

Type: News Item

Postpartum care after gestational diabetes is preconception care as well

Posted on: 07/01/2014 - 20:05

WASHINGTON – The rise in gestational diabetes cases demands new strategies for active postpartum care that will not only assist with prevention of type 2 diabetes, but will also prepare women for...

Field of Interest: Endocrinology

Type: News Item

Newsletters

Stay informed on our latest news!

You are here

FDA to probe saxagliptin’s heart failure risk

‘Obesity paradox’ refuted

FDA approves dapagliflozin for type 2 diabetes

Postpartum care after gestational diabetes is preconception care as well

Newsletters

Latest Newsletters